EnglishGermanHebrewKorean
  • CEO
Maxiplus
Global Healthcare Group
The Best Partner for You

R&D Projects

We offer new treatment such as innovative new drugs (chemical, bio), stem cell treatment, modified new drugs, etc

Introduction of Pipeline

The MAXIPLUS MEDICAL & PHARMACEUTICAL Research Headquarters is focusing on R&D in fields with high market demands such as chronic diseases, hard-to-cure diseases, and for improving quality of life, and we will provide patients with innovative new drugs (chemical, bio), and new treatment such as stem cell treatment and modified new drugs.
Innovative
new drugs
Gatroesophageal reflux disease treatment drugs
Diabetes treatment drugs
Fibrosis treatment drugs
Autoimmunity treatment drugs
Chronic pain treatment drugs
Biologic Drug,
Stem Cell Therapy
Dry eye syndrome treatment drugs
Immunology anti-cancer drug
Stem cell treatment drugs
Incrementally
Modified Drug(IMD)
Combination Drug & Extended-Release modified Drugs
Sustained Release Injectable Drugs

R&D Projects

  1. Research

    • DWJ215 Hearing difficulties
    • DWJ816S001 Anti-cancer
    • DWJ816S002 Anti-cancer
    • HL186 Immunology anti-cancer drug
    • HL187 Immunology anti-cancer drug
    • DWP458 Osteoporosis
    • DWP457 Type 1 diabetes
    • DWP820S008 Asthma

  2. Pre-clinical

  3. PhaseⅠ

  4. PhaseⅡ

  5. PhaseⅢ

    • HL036 Dry eye syndrome
    • Furestem-CD Crohn disease

  6. NDA

Fexuprazan
(NDA)
Gastroesophageal Reflux Disease Best-in-Class - New drug pipeline being developed with the goal of best new drugs in series
‘Fexuprazan’ is a next-generation drug for gastroesophageal reflux disease with P-CAB mechanism that submitted a drug applcation to the Ministry of Food and Drug Safety (MFDS) after completing domestic phase 3 clinical trials. Fexuprazan is a treatment for gastroesophageal reflux disease that reversibly blocks proton pumps from secreting gastric acid in the stomach.
DWP213388
Graft-Versus-Host Disease First-in-Class World's First Innovative New Drug Pipeline
‘DWP213388’ is an oral dosage form of another autoimmune disease drug candidate with a mechanism that selectively suppresses ITK (Interleukin-2-inducible T-cell kinase) and BTK (Bruton's tyrosine kinase), which are targets involved in activating immune cells (T cell and B cell). We are striving to develop a leading global drug to treat patients with graft-versus-host disease and autoimmune diseases in which effective treatment options are insufficient.
DWP16001
SGLT2 Diabetes Best-in-Class - New drug pipeline being developed with the goal of best new drugs in series
‘DWP16001’ shows better effect and longer duration than existing products through a SGLT-2 suppression mechanism for treatment of type 2 diabetes, and R&D is being conducted with the goal of receiving approval for sales in 2023 by recently beginning Phase 2 clinical trial.
DWP17061
Arthritis Pain First-in-Class World's First Innovative New Drug Pipeline
‘DWP17061’ is a treatment for chronic pain being developed with indication for arthritis and it blocks Nav1.7, a sodium channel.
DWP212525
Pemphigus First-in-Class World's First Innovative New Drug Pipeline
‘DWP212525’ is an oral dosage form autoimmune disease treatment candidate that selectively suppresses JAK3 and TFK involved in activating cells of the immune system (T cell and B cell). We are currently focusing on research to develop various autoimmune disease treatments for pemphigus for which an effective treatment is yet nonexistent, rheumatic arthritis and inflammatory bowel disease.
DWN12088
Idopathic Pulmonary Fibrosis First-in-Class - New drug pipeline being developed for the first time in the world
‘DWN12088’ is the first pulmonary fibrosis drug being developed in the world and it is a first-in-class pulmonary fibrosis drug with a new mechanism that suppresses excessive generation of collagen, a cause of pulmonary fibrosis, by reducing the action of Prolyl-tRNA synthetase (PRS) protein. It was selected as a supported project by the pan-government new drug development team in March 2019 and was designated as a orphan drug by the US FDA in August.

Stem cell treatment medicine

DW-MSC[mesenchymal stem cell]

DW-MSC [mesenchymal stem cell] is under development as a drug for rare/difficult-to-cure diseases and degenerative diseases as well as a genetic delivery platform to strengthen stem cell functions. As a Stem cell treatment, DW-MSC is being developed with indications for acute pancreatitis, stroke, dementia, cerebral atrophy, and idiopathic pulmonary fibrosis. ‘DW-MSC’ pioneers in mass production in Isreal, procuring competitiveness for commercialization of stem cell lines We aim to develop a world-class stem cell treatment through convergence of smart stem cell technologies that can maximize effects through Cell & Gene technologies.

Incrementally Modified Drug(IMD)

Development of future-oriented platform-based new modified drugs

MAXIPLUS MEDICAL & PHARMACEUTICAL has strengthened the pipeline for modified new drugs using platform technologies (oral dosage forms such as core tablets, multi-layer tablets, multi-filling capsules, and long acting depot injections based on microsphere/nano technology), developing 2-in-1, 3-in-1, 4-in-1 combination drugs, multi-delivery sustained release oral forms and long-acting depot injections to continuously develop new products, and it is also pursuing life cycle extension of key products that form the brand image of MAXIPLUS MEDICAL & PHARMACEUTICAL.